mutations in chronic lymphocytic leukemia - uncommon and unfavorable.
作者信息
Tausch Eugen, Stilgenbauer Stephan
机构信息
Department of Internal Medicine III, Ulm University, Ulm, Germany.
出版信息
Haematologica. 2020 Jan 31;105(2):255-256. doi: 10.3324/haematol.2019.238691. Print 2020.
Abstract
摘要
相似文献
1
mutations in chronic lymphocytic leukemia - uncommon and unfavorable.慢性淋巴细胞白血病中的突变——罕见且预后不良。
Haematologica. 2020 Jan 31;105(2):255-256. doi: 10.3324/haematol.2019.238691. Print 2020.
2
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.接受一线治疗的慢性淋巴细胞白血病患者的NOTCH1、SF3B1、BIRC3和TP53突变：与生物学参数及治疗反应的相关性
Leuk Lymphoma. 2014 Dec;55(12):2785-92. doi: 10.3109/10428194.2014.898760.
3
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression.del(11q) 慢性淋巴细胞白血病进展中单等位基因和双等位基因 BIRC3 缺失的生物学意义。
Blood Cancer J. 2021 Jul 9;11(7):127. doi: 10.1038/s41408-021-00520-5.
4
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.11号染色体缺失的慢性淋巴细胞白血病患者中双等位基因BIRC3失活可识别出具有非常侵袭性疾病的一个亚组。
Br J Haematol. 2019 Apr;185(1):156-159. doi: 10.1111/bjh.15405. Epub 2018 May 22.
5
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.CD49d 优于新型复发突变，是慢性淋巴细胞白血病总生存的独立预后因子。
Leukemia. 2016 Oct;30(10):2011-2018. doi: 10.1038/leu.2016.88. Epub 2016 Apr 25.
6
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.慢性淋巴细胞白血病诊断时的广泛二代测序分析：临床与生物学相关性
J Hematol Oncol. 2016 Sep 15;9(1):88. doi: 10.1186/s13045-016-0320-z.
7
NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.慢性淋巴细胞白血病中的 NF-κB 激活：外部触发因素和内在病变的交汇点。
Semin Cancer Biol. 2016 Aug;39:40-8. doi: 10.1016/j.semcancer.2016.07.005. Epub 2016 Aug 1.
8
Reply to Aron P. Kater .回复阿隆·P·卡特。
Haematologica. 2020 Jul;105(7):e384. doi: 10.3324/haematol.2020.255596.
9
Next-generation sequencing in chronic lymphocytic leukemia.慢性淋巴细胞白血病的下一代测序。
Semin Hematol. 2013 Oct;50(4):286-95. doi: 10.1053/j.seminhematol.2013.09.005.
10
[The correlation of CD49d expression pattern with molecular genetics and hotspot gene mutants in patients with chronic lymphocytic leukemia].[慢性淋巴细胞白血病患者CD49d表达模式与分子遗传学及热点基因突变的相关性]
Zhonghua Xue Ye Xue Za Zhi. 2022 Jun 14;43(6):463-468. doi: 10.3760/cma.j.issn.0253-2727.2022.06.004.
引用本文的文献
1
Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.慢性淋巴细胞白血病中基因畸变与信号通路相互作用的见解：从发病机制到治疗策略
Biomark Res. 2024 Dec 28;12(1):162. doi: 10.1186/s40364-024-00710-w.
2
Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations.与荧光原位杂交（FISH）相比，靶向测序在检测慢性淋巴细胞白血病拷贝数改变方面的效用
Cancers (Basel). 2024 Jul 3;16(13):2450. doi: 10.3390/cancers16132450.
3
In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.深入的淋巴浆细胞分化淋巴瘤的分子分析可为更精确的诊断和合理的治疗分配提供依据。
Ann Hematol. 2024 Feb;103(2):553-563. doi: 10.1007/s00277-023-05531-9. Epub 2023 Nov 11.
4
Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma.病例报告：复合套细胞淋巴瘤和经典霍奇金淋巴瘤。
Pathol Oncol Res. 2023 Mar 17;29:1611051. doi: 10.3389/pore.2023.1611051. eCollection 2023.
5
Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.对小鼠 CLL 的纵向分析确定了与白血病相关的克隆变化，包括 Myc 增益，这预示着患者的预后不良。
Leukemia. 2022 Feb;36(2):464-475. doi: 10.1038/s41375-021-01381-4. Epub 2021 Aug 20.
6
Copy Number Variation and Rearrangements Assessment in Cancer: Comparison of Droplet Digital PCR with the Current Approaches.癌症中拷贝数变异和重排的评估：液滴数字 PCR 与现行方法的比较。
Int J Mol Sci. 2021 Apr 29;22(9):4732. doi: 10.3390/ijms22094732.
7
BIRC3 and BIRC5: multi-faceted inhibitors in cancer.BIRC3和BIRC5：癌症中的多面抑制剂
Cell Biosci. 2021 Jan 7;11(1):8. doi: 10.1186/s13578-020-00521-0.
本文引用的文献
1
Biological and clinical implications of mutations in chronic lymphocytic leukemia.慢性淋巴细胞白血病中 突变的生物学和临床意义。
Haematologica. 2020 Jan 31;105(2):448-456. doi: 10.3324/haematol.2019.219550. Print 2020.
2
BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.BIRC3 表达通过增强 NF-κB 核易位预测 CLL 进展并定义治疗敏感性。
Clin Cancer Res. 2019 Mar 15;25(6):1901-1912. doi: 10.1158/1078-0432.CCR-18-1548. Epub 2018 Nov 28.
3
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.在既往治疗的 CLL/SLL 患者中，3 期 RESONATE 研究中高危预后因素的延长随访及影响。
Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8.
4
Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.慢性淋巴细胞白血病中克隆性和亚克隆性TP53、SF3B1、BIRC3、NOTCH1和ATM突变的临床影响
Blood. 2016 Apr 28;127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2.
5
Mutations driving CLL and their evolution in progression and relapse.驱动慢性淋巴细胞白血病的突变及其在疾病进展和复发中的演变。
Nature. 2015 Oct 22;526(7574):525-30. doi: 10.1038/nature15395. Epub 2015 Oct 14.
6
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.反复出现的突变可改善慢性淋巴细胞白血病的预后。
Leukemia. 2015 Feb;29(2):329-36. doi: 10.1038/leu.2014.196. Epub 2014 Jun 19.
7
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.ATM突变而非BIRC3缺失和/或突变预示着11号染色体缺失的慢性淋巴细胞白血病患者生存率降低：来自英国LRF CLL4试验的数据。
Haematologica. 2014 Apr;99(4):736-42. doi: 10.3324/haematol.2013.098574. Epub 2014 Feb 28.
8
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.BTK 抑制可通过其对 B 细胞受体信号活性的影响来靶向体内 CLL 增殖。
Leukemia. 2014 Mar;28(3):649-57. doi: 10.1038/leu.2013.358. Epub 2013 Nov 25.
9
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia.BIRC3 缺失与 TP53 野生型慢性淋巴细胞白血病氟达拉滨耐药相关。
Blood. 2012 Mar 22;119(12):2854-62. doi: 10.1182/blood-2011-12-395673. Epub 2012 Feb 3.
10
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.SF3B1 剪接因子在慢性淋巴细胞白血病中的突变：与进展和氟达拉滨耐药性相关。
Blood. 2011 Dec 22;118(26):6904-8. doi: 10.1182/blood-2011-08-373159. Epub 2011 Oct 28.
Zotero 插件